Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XH Histone deacetylase (HDAC) inhibitors
L01XH03 Panobinostat
D10019 Panobinostat lactate (JAN)
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Panobinostat
D10019 Panobinostat lactate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG03133 Histone deacetylase inhibitor
DG01403 Panobinostat
D10019 Panobinostat lactate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01403 Panobinostat
D10019 Panobinostat lactate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG01403 Panobinostat
D10019 Panobinostat lactate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Histone deacetylase
HDAC
D10019 Panobinostat lactate (JAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10019
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10019
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10019
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10019
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10019
Drug groups [BR:br08330]
Antineoplastic
DG03133 Histone deacetylase inhibitor
DG01403 Panobinostat
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01403 Panobinostat
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG01403 Panobinostat